Royalty Pharma’s $2 billion IPO target shows importance of patent monetisation in life sciences

The company’s public offering comes after years of growth and demonstrates the changing dynamics of an industry in which smaller R&D entities are becoming increasingly significant players


Get unlimited access to all IAM content